Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
29 Février 2024 - 10:01PM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an
advanced gene editing company utilizing its novel proprietary
ARCUS® platform to develop in vivo gene editing therapies for
sophisticated gene edits, including gene insertion, excision, and
elimination, today announced the commencement of a proposed
underwritten public offering of its common stock and accompanying
warrants to purchase shares of common stock, including pre-funded
warrants to purchase common stock in lieu of common stock for
certain purchasers. All shares of common stock, pre-funded warrants
and accompanying warrants to be sold in the proposed offering will
be sold by Precision. The pre-funded warrants will be issued to
certain purchasers who have elected to purchase them in lieu of
shares of common stock in this offering.
Precision also expects to grant the underwriters a 30-day option
to purchase up to an additional 15% of the total number of shares
of common stock and warrants to purchase shares of common stock
(including shares underlying the pre-funded warrants) to be offered
at the public offering price, less the underwriting discount. The
offering is subject to market and other conditions and there can be
no assurance as to whether or when the offering may be completed,
or as to the actual size or terms of the offering.
Guggenheim Securities, LLC is acting as sole book-running
manager for the offering.
The securities described above are being offered pursuant to an
effective shelf registration statement (File No. 333-272540) that
was filed with the U.S. Securities and Exchange Commission (“SEC”)
on June 9, 2023. This offering will be made only by means of a
prospectus supplement and the accompanying prospectus that forms a
part of the effective shelf registration statement.
A preliminary prospectus supplement related to the offering
(including the accompanying prospectus) will be filed with the SEC
and will be available on the SEC’s website located at www.sec.gov.
Copies of the preliminary prospectus supplement and the
accompanying prospectus may also be obtained, when available, by
contacting: Guggenheim Securities, LLC, Attention: Equity Syndicate
Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by
telephone at (212) 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
the securities in this offering in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company
dedicated to improving life (DTIL) with its novel and proprietary
ARCUS® genome editing platform that differs from other technologies
in the way it cuts, its smaller size, and its simpler structure.
Key capabilities and differentiating characteristics may enable
ARCUS nucleases to drive more intended, defined therapeutic
outcomes. Using ARCUS, Precision’s pipeline is comprised of in vivo
gene editing candidates designed to deliver lasting cures for the
broadest range of genetic and infectious diseases where no adequate
treatments exist.
Forward-Looking Statements
Certain statements contained in this press release, including
those relating to the timing and size of the offering, the grant of
the option to purchase additional shares of common stock,
pre-funded warrants and/or warrants, and other statements relating
to the proposed offering, are forward-looking statements that
involve a number of risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks and uncertainties associated with the
consummation of the proposed offering, uncertainties related to
market conditions, the satisfaction of customary closing conditions
related to the proposed offering, the completion of the offering on
the anticipated terms or at all, general economic conditions and
other risks identified from time to time in the reports Precision
files with the SEC, including its Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and
the preliminary prospectus supplement and accompanying prospectus
related to the proposed offering to be filed with the SEC, which
are or will become available at www.sec.gov. The forward-looking
statements in this press release speak only as of the date of this
document, and Precision undertakes no obligation to update or
revise any of the statements. Precision’s business is subject to
substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give
careful consideration to these risks and uncertainties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229371526/en/
Investor and Media Contact: Naresh Tanna Vice President
of Investor Relations Naresh.tanna@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Precision BioSciences (NASDAQ:DTIL)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024